CytomX Therapeutics, a clinical-stage biopharmaceutical company specializing in conditionally activated biologics for cancer treatment, will announce its third quarter 2026 financial results on November 5, 2026, after U.S. market close. The company will host a conference call and webcast to discuss the results. CytomX is advancing innovative cancer therapies including Varsetatug masetecan for metastatic colorectal cancer and CX-801 for metastatic melanoma, with collaborations involving Amgen, Regeneron, and Moderna. Investors and interested parties can access the webcast via CytomX's website.
CytomX Therapeutics is set to report its third quarter 2026 financial results on November 5, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced US health stocks, 95 rose and 47 fell. Notable movers include Tenet Healthcare Corporation (THC) at USD 254.80 with a 1-day change of -5.10%, Eli Lilly And Co (LLY) at USD 1,341.75 with a 1-day change of +4.11%, and Amgen, Inc. (AMGN) at USD 468.17 with a 1-day change of +3.62%.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
